TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19167684
Drug: Platinum-based salvage
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based salvage chemotherapy, high-dose therapy, and autologous stem cell transplantation (ASCT) for PET-positive patients
Study: 19167684
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy for PET-negative patients
Study: 11311997
Drug: Synthetic, monovalent,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic, monovalent, octameric HIV‐1 MN V3 peptide in aluminum hydroxide (alum) adjuvant administered by intramuscular delivery
Study: 11311997
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of the vaccine (encapsulated in biodegradable micro‐spheres)
Study: 11311997
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oral administration with parenteral boosting
Study: 9159559
Drug: Oral lamotrigine
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral lamotrigine monotherapy for up to 48 weeks
Study: 22806208
Drug: Tamsulosin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.2 mg/day orally for 7 days)
Study: 8776832
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g pectin
Study: 8776832
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g pectin
Study: 8776832
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g pectin
Study: 29654805
Drug: SER120 intranasal
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: SER120 intranasal spray 0.83 mcg
Study: 29654805
Drug: SER120 intranasal
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: SER120 intranasal spray 1.66 mcg
Study: 16562807
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (PN) supplemented with glutamine (0.4 g/kg/day of L-alanine-L-glutamine)
Study: 18596311
Drug: Standard parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard parenteral nutrition (PN)
Study: 12792701
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg kg‐1 day‐1 ursodeoxycholic acid for three months
Study: 10234869
Drug: Reflexological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reflexological treatment for headache
Study: 1655987
Drug: Three or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three or four drugs plus whole-lung irradiation
Study: 1655987
Drug: Two or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two or three drugs without whole-lung irradiation
Study: 6661381
Drug: Brotizolam (0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brotizolam (0.50 mg)
Study: 30698675
Drug: Pre-treatment genotyping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment genotyping (genotype-guided thiopurine dosing)
Study: 27883215
Drug: Immunomodulator combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunomodulator combination therapy
Study: 27382454
Drug: Deferasirox (DFX)
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferasirox (DFX) - single oral daily dose of 20-40 mg/kg/day
Study: 27382454
Drug: Deferoxamine (DFO)
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deferoxamine (DFO) - 20-50 mg/kg/day via subcutaneous infusion over 8-10 hours, 5 days a week
Study: 21878578
Drug: 25 µg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 µg/h reservoir with heat
Study: 21878578
Drug: 25 µg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 µg/h matrix with heat
Study: 21878578
Drug: 50 µg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 µg/h reservoir without heat
Study: 21878578
Drug: 25 µg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 µg/h reservoir without heat
Study: 21878578
Drug: 25 µg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 µg/h matrix without heat
Study: 17205576
Drug: No postsurgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: No postsurgical treatment
Study: 15889357
Drug: Telavancin (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telavancin (administered intravenously once daily)
Study: 15889357
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (antistaphylococcal penicillin 4 times daily or vancomycin twice daily)
Study: 11281611
Drug: Octreotide (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (0.1 mg sc) during exercise
Study: 11281611
Drug: Octreotide (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (0.1 mg sc) after exercise
Study: 11281611
Drug: Octreotide (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (0.1 mg sc) without exercise
Study: 7942182
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of interferon and ACNU in addition to radiotherapy (IAR therapy)
Study: 7942182
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy with radiation and chemotherapy
Study: 2946583
Drug: Prednisone 10
Normalized name: prednisone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 10 mg X 3 daily
Study: 2946583
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) orally 500 mg daily
Study: 2946583
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) i.m. 1000 mg daily for 3 weeks followed by 500 mg i.m. weekly
Study: 23993028
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume (5 mL/kg + 5 cm H2O positive end-expiratory pressure) preserved ventilation (PV)
Study: 23993028
Drug: Conventional tidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional tidal volume (8 mL/kg) controlled ventilation (CV)
Study: 22010223
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg hydrogen sulfide from wk 0 to 3 and 3 mg/kg from wk 4 to 6
Study: 22010223
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg hydrogen sulfide from wk 0 to 3 and 6 mg/kg from wk 4 to 6
Study: 22010223
Drug: 8 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg/kg hydrogen sulfide from wk 0 to 3 and 12 mg/kg from wk 4 to 6
Study: 16600069
Drug: Mind Reading
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mind Reading software used at home with weekly tutor sessions
Study: 1404051
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment of manipulation and application of plaster of Paris
Study: 7152079
Drug: Alclometasone cream
Normalized name: alclometasone Topical Cream
DrugBank: Alclometasone (DB00240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alclometasone cream 0.05% applied twice a day for 21 days
Study: 7152079
Drug: Clobetasone butyrate
Normalized name: clobetasone butyrate
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Clobetasone butyrate cream 0.5% applied twice a day for 21 days
Study: 27677487
Drug: Protein-Enriched Diet
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-Enriched Diet (PED) with protein intake 2.0 g/kg of ideal body weight
Study: 27677487
Drug: Normal Protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Protein Diet (NPD) with protein intake 1.0 g/kg of ideal body weight
Study: 27233490
Drug: Anemia (hemoglobin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anemia (hemoglobin level ≤ 6.0 mmol/L or 9.7 g/dL)
Study: 22833684
Drug: Primary tumour
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary tumour resection plus systemic therapy
Study: 17064199
Drug: ICA-17043 50
Normalized name: ICA-105665
DrugBank: ICA-105665 (DB06089)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICA-17043 50 mg
Study: 17064199
Drug: ICA-17043 100
Normalized name: ICA-105665
DrugBank: ICA-105665 (DB06089)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICA-17043 100 mg
Study: 17064199
Drug: ICA-17043 150
Normalized name: ICA-105665
DrugBank: ICA-105665 (DB06089)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICA-17043 150 mg
Study: 12588578
Drug: Exercise and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise and incontinence care provided every 2 hours from 8:00 a.m. to 4:30 p.m. (total of four daily care episodes) 5 days a week for 32 weeks
Study: 8934060
Drug: Norplant implants
Normalized name: Norplant 3-oxime
DrugBank: Norelgestromin (DB06713)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norplant implants users
Study: 1751913
Drug: Systemic and
Normalized name: Estradiol and Levonorgestrel Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic and periocular steroid therapy
Study: 7042090
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with MOPP and ABDV given in alternating months; Radiation therapy (RT) (2000 rad in 2 weeks) during Month 5
Study: 28821315
Drug: Starch-entrapped microspheres
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starch-entrapped microspheres (SM) 9 or 12 g
Study: 28821315
Drug: Psyllium (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium (12 g)
Study: 26357934
Drug: Group S
Normalized name: Blood group substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group S (supine position immediately after injection)
Study: 24083593
Drug: Treatment Region
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Region (TR)
Study: 18941065
Drug: Dynamic contrast-enhanced
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic contrast-enhanced MRI before and after two cycles of chemotherapy
Study: 12508078
Drug: High amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: High amino acid intake (HAA) at 3 g.kg(‐1).d(‐1)
Study: 8558194
Drug: Fluorouracil (5FU)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil (5FU) based chemotherapy: 200 mg/m2/d for 3 weeks with leucovorin 20 mg/m2/w, plus Cisplatin 100 mg/m2 on day 1
Study: 8558194
Drug: Fluorouracil (5FU)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil (5FU) based chemotherapy
Study: 6630314
Drug: Oral papaverine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral papaverine (600 mg)
Study: 6630314
Drug: Intravenous papaverine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous papaverine (100 mg)
Study: 23143142
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT), administered two times per week for 4 weeks, n = 12
Study: 22947909
Drug: Atorvastatin and
Normalized name: atorvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin and antihistamines
Study: 22947909
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and antihistamines (Control group)
Study: 18926645
Drug: D-amphetamine (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-amphetamine (0, 15, and 30 mg/day)
Study: 18926645
Drug: Cocaine (4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (4, 30, 60 mg, i.n.)
Study: 18926645
Drug: D-amphetamine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-amphetamine (30 mg/day)
Study: 18926645
Drug: D-amphetamine (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-amphetamine (0 mg/day)
Study: 17698275
Drug: Quetiapine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (up to 400 mg/day)
Study: 15010743
Drug: Warfarin (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (not specified dosage or duration)
Study: 9203245
Drug: Remacemide hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remacemide hydrochloride (300 mg single dose, 150 mg or 300 mg twice daily for 14 days)
Study: 9203245
Drug: Remacemide hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remacemide hydrochloride (150 mg twice daily)
Study: 9203245
Drug: Remacemide hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remacemide hydrochloride (300 mg twice daily)
Study: 27553205
Drug: Split-dose 2L-PEGA
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose 2L-PEGA
Study: 27553205
Drug: Single-dose 4L-PEG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose 4L-PEG
Study: 27553205
Drug: Split-dose 4L-PEG
Normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose 4L-PEG
Study: 23376362
Drug: Peginterferon (PegIFN)
Normalized name: peginterferon alfa-2a Injection [Pegasys]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon (PegIFN) therapy for 52 weeks
Study: 19963403
Drug: Sodium hyaluronate
Normalized name: sodium hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium hyaluronate (ARTZ Dispo) 25 mg/wk for 5 weeks
Study: 16905181
Drug: High-risk cardiovascular
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-risk cardiovascular prevention approach including complete registration of risk factors, optimization of medical treatment, and health counseling on high fat consumption, smoking, and physical inactivity.
Study: 8460758
Drug: Morphine at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine at 1 mg.h-1 combined with ketamine at 5 mg.h-1
Study: 8460758
Drug: Morphine at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine at 1 mg.h-1 combined with ketamine at 10 mg.h-1
Study: 8460758
Drug: Morphine at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine at 1 mg.h-1 combined with ketamine at 20 mg.h-1
Study: 8460758
Drug: Morphine at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine at 1 mg.h-1 alone
Study: 31902378
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids from flaxseed oil (2 × 1000 mg/d, containing 400 mg α-linolenic acid per capsule)
Study: 27825572
Drug: Ice (30min,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice (30min, applied twice at 8h interval)
Study: 27825572
Drug: Cold CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold CO2 (2min, applied twice at 8h interval)
Study: 26000667
Drug: 8 mL
Normalized name: ethanol 0.8 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mL of 0.5% lidocaine (group L)
Study: 26000667
Drug: 6 mL
Normalized name: ethanol 0.6 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mL of 0.5% lidocaine mixed with 80 mg (2 mL) of methylprednisolone acetate (group LS)
Study: 26000667
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (L and LS)
Study: 23433200
Drug: Probiotic compound
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic compound (seven bacterial species including Lactobacillus and Bifidobacterium strains and Streptococcus thermophiles)
Study: 23433200
Drug: Probiotic compound
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic compound
Study: 23433200
Drug: Probiotic compound
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic compound and Placebo
Study: 21840828
Drug: Highly Purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly Purified Follicle Stimulating Hormone (HP-FSH)
Study: 21840828
Drug: Recombinant Follicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant Follicle Stimulating Hormone (rFSH)
Study: 10095928
Drug: Escherichia coli
Normalized name: escherichia coli
DrugBank: Escherichia coli (DB16539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escherichia coli resistant to antibiotics
Study: 10095928
Drug: Escherichia coli
Normalized name: escherichia coli
DrugBank: Escherichia coli (DB16539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escherichia coli resistant to various antibiotics
Study: 10095928
Drug: Escherichia coli
Normalized name: escherichia coli
DrugBank: Escherichia coli (DB16539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escherichia coli resistant to five or more antibiotics
Study: 14621746
Drug: PGE1 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE1 (40 microg/kg twice a day, intravenously from day 1 to day 7)
Study: 414280
Drug: L-Dopa (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Dopa (1.5 g)
Study: 414280
Drug: Aminophylline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (200 mg)
Study: 414280
Drug: Aminophylline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (200 mg) plus Ephedrine (50 mg)
Study: 28679605
Drug: Direct NIV
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct NIV discontinuation (n=59)
Study: 26118825
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg every-other-week
Study: 26118825
Drug: Adalimumab 80
Normalized name: ADALIMUMAB 80MG/0.8ML INJ PEN KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 80 mg every-other-week
Study: 26118825
Drug: Dose escalation
Normalized name: PALFORZIA Initial Dose Escalation KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation to 80 mg every-other-week for patients with suboptimal response to 40 mg
Study: 26118825
Drug: Adalimumab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (both doses)
Study: 21717822
Drug: Policosanol 20
Normalized name: POLICOSANOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol 20 mg/day for 12 weeks
Study: 11166969
Drug: MST (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: MST (oral retarded morphine sulphate)
Study: 9731991
Drug: Lansoprazole in
Normalized name: lansoprazole Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole in combination with antibiotics (amoxicillin, clarithromycin, metronidazole, or tinidazole)
Study: 9731991
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy including lansoprazole
Study: 9731991
Drug: Lansoprazole vs.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole vs. other PPIs (e.g., omeprazole)
Study: 7987362
Drug: L-carnitine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine supplementation (4 g/day for 14 days)
Study: 7987362
Drug: L-carnitine (L-CN,
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (L-CN, Day 28)
Study: 31633844
Drug: Ampicillin-sulbactam plus
Normalized name: ampicillin / sulbactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin-sulbactam plus amoxicillin-clavulanic acid
Study: 31633844
Drug: Erythromycin plus
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin plus ampicillin plus amoxicillin
Study: 23782590
Drug: TAU +
Normalized name: Interferon tau
DrugBank: Interferon tau (DB16972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU + SWT (Treatment As Usual + Structured Writing Therapy)
Study: 23782590
Drug: TAU (Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU (Treatment As Usual)
Study: 20479668
Drug: Oral gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral gabapentin 900 mg plus normal saline infiltration (G)
Study: 20479668
Drug: Oral gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral gabapentin 900 mg plus 2% lidocaine infiltration (GL)
Study: 20479668
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo plus 2% lidocaine infiltration (L)
Study: 20479668
Drug: Oral gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral gabapentin 900 mg (G)
Study: 14656787
Drug: Face mask
Normalized name: CVS Face Masks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face mask at 5 L*min(‐1)
Study: 14656787
Drug: Mike Cannula
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mike Cannula at 5 L*min(‐1)
Study: 11448573
Drug: CR (20.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR (20.0 g of CR/d for 7 d followed by 10.0 g of CR/d for 14 d)
Study: 11448573
Drug: HMB (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB (3.0 g of HMB/d)
Study: 7804510
Drug: Urapidil (U)
DrugBank: Urapidil (DB12661)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil (U) - bolus of 25 mg; initial infusion rate of 15-85 micrograms/kg/min; maintenance infusion rate of 2-7 micrograms/kg/min
Study: 7804510
Drug: Sodium Nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium Nitroprusside (S) - initial infusion rate of 1-2 micrograms/kg/min; maintenance infusion rate of max. 5 micrograms/kg/min
Study: 30189012
Drug: Oxycodone/naloxone (5/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone/naloxone (5/2.5 or 10/5 mg) during haemodialysis
Study: 30189012
Drug: Oxycodone/naloxone (5/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone/naloxone (5/2.5 or 10/5 mg) between haemodialysis sessions
Study: 27973690
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading after implant placement (N = 81, group A)
Study: 22639013
Drug: 1.8 g
Normalized name: Calciquid, 1.8 g/5 mL oral syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 g of sodium
Study: 22639013
Drug: 3.8 g
Normalized name: dextrin 3 gram/3.8 gram ORAL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.8 g of sodium
Study: 22639013
Drug: Sodium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium intake <4.5 g/day